At the intersection between children and older adults, the care of adolescent and young
adult (AYA) patients with acute lymphoblastic leukemia (ALL) poses unique challenges and …

The mechanisms through which immune responses are generated against solid cancers are
well characterized and knowledge of the immune evasion pathways exploited by these …

The treatment of acute promyelocytic leukemia (APL) has evolved rapidly in the past two
decades after the introduction of highly active drugs, including tretinoin (all-trans-retinoic …

Type I interferon (IFN), essential for spontaneous T cell priming against solid tumors, is
generated through recognition of tumor DNA by STING. Interestingly, we observe that type I …

Purpose: The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in
70% to 80% of patients with acute myelogenous leukemia (AML), is unknown. Experimental …

Background Novel therapies for patients with acute myeloid leukemia (AML) are imperative,
particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor …

Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in
relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for …

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed treatment paradigms for
relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) in children and younger …

The availability and use of blinatumomab symbolizes a paradigm shift in the management of
B-cell acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter cohort …

Background Males have a higher incidence of medulloblastoma (MB) than females, but the
effect of gender on survival is unclear. Studies have yielded conflicting results, possibly due …